Leiden

• A study evaluating the safety and efficacy of anti-CD19 CAR T in subjects with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Ended
  2022-501686-47-00 7 2022-02-28 relapsed/refractory chronic lymphocytic leukemia relapsed/refractory s
• A study to evaluate ExPEC9V vaccine for the prevention of Invasive E. coli Disease in adults aged 60 years and older with a history of urina … Ended
  2023-506589-30-00 5 2022-02-09 Invasive Extraintestinal Pathogenic Escherichia coli Disease
• Sarcomas and DDR-Inhibition; a neoadjuvant phase I combined modality study - SADDRIN-1 Ended
  2024-514907-32-00 3 2022-01-21 non-metastatic soft tissue sarcoma
• A multi site clinical trial to evaluate the efficacy and safety of Qutenza® in subjects with post-surgical neuropathic pain Ended
  2024-514934-19-00 5 2021-11-08 Post-surgical neuropathic pain
• Pembrolizumab Plus Lenvatinib in Combination with Belzutifan in Solid Tumors Ended
  2023-503905-12-00 4 2021-08-20 Liver cancer; Colon cancer; Pancreatic cancer; Bile Duct or Gallbladde
• "A Phase 3 study of Viltolarsen in boys with Duchenne Muscular Dystrophy (DMD)" Ended
  2023-507146-91-00 5 2021-06-07 Duchenne Muscular Dystrophy (DMD)
• Investigation to assess the effects of zalunfiban in patients with an acute heart attack Ended
  2023-508485-15-00 5 2021-04-22 Subjects with documented STEMI, presenting with persistent ischemic ch
• A Multicentre, Open-Label, Single Ascending Dose, Dose-Ranging, Phase I/IIa Study to Evaluate the Safety and Tolerability of an Autologous A … Ended
  2024-512579-11-00 7 2021-03-17 Prophylaxis against renal transplant rejection
• Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Efficacy (Part B) in Participants With Duchenne Muscu … Ended
  2023-509935-23-00 4 2020-08-21 Duchenne Muscular Dystrophy
• Study to evaluate the addition of an experimental drug, CC-90010, to the usual treatment of brain cancer after surgery Ended
  2024-511171-15-00 3 2020-07-06 Subjects with newly diagnosed WHO Grade IV glioblastoma (ndGBM) who ha
• Safety, immunogenicity and preliminary clinical activity study of PDC*lung01 cancer vaccine in NSCLC Ended
  2024-517429-24-00 7 2020-01-09 Non-small-cell lung cancer
• A Prospective Phase III Multi-center, 2-Year Placebo Controlled, Double Blind Study to Evaluate the Efficacy and Safety of "Kamada-AAT for I … Ended
  2024-516054-21-00 5 2019-10-25 Adult Patients with Congenital Alpha-1 Antitrypsin Deficiency with Mod
• OPTIMIZE Ended
  2024-516509-22-00 6 2019-07-22 kidney transplant
• A phase 1 study of oral Debio 0123 in combination with carboplatin in patients with advanced solid tumors Ended
  2024-510984-52-00 1 2019-05-24 Patients with tumors
• A randomized trial to investigate the reset of humoral autoimmunity by combining belimumab with rituximab in severe systemic lupus erythemat … Ended
  2023-507867-20-00 10 2018-10-04 Lupus Erythematosus, Systemic
• Blinatumomab added to prephase and consolidation therapy in precursor B-acute lymphoblastic leukemia in adults. Ended
  2024-511050-44-00 4 2018-05-16 Precursor B-acute lymphoblastic leukemia
• A phase I dose finding study of oral TNO155 in adult patients with advanced solid tumors Ended
  2023-508925-29-00 1 2017-06-29 Advanced solid tumors
• A study of Ibrutinib in combination with Rituximab versus Placebo in combination with Rituximab in treatment of patients with Follicular Lym … Ended
  2023-507271-21-00 5 2017-04-11 Follicular Lymphoma
• GIVE trial (Gazyvaro In combination with VEnetoclax in Elderly CLL) Ended
  2024-511048-22-00 4 2016-10-27 Chronic lymphocytic leukemia
• autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized Europea … Ended
  2024-511235-10-00 5 2016-07-25 Generalized mantle cell Lymphoma
• HD21 Ended
  2024-518022-33-00 5 2016-07-15 Advanced Stage of Hodgkin Lymphoma
• Phase 1/2 Study of AOC 1020 in Adults with Facioscapulohumeral Muscular Dystrophy (FSHD) Ended
  2022-502096-32-00 7 Facioscapulohumeral muscular dystrophy (FSHD)
• A study evaluating the safety, tolerability, and efficacy of GLPG5101 in adults with treatment-refractory active systemic lupus erythematosu … Ended
  2023-504422-19-00 3 Treatment-refractory active systemic lupus erythematosus
• STRIDER: A phase II Study evaluaTing intRacranial effIcacy of JDQ443 in patiEnts with KRAS G12C+ NSCLC and bRain metastases Ended
  2023-505721-13-00 4 patients with KRAS G12C+ non small cell lung cancer and brain metastas

Showing 433–456 of 459 trials